Canaccord lowered the firm’s price target on Neurocrine (NBIX) to $163 from $172 and keeps a Buy rating on the shares. The firm said management issued a 2025E sales outlook for Ingrezza of $2.5-2.6bn, which translates to lower growth than investors expected, and higher operating expense numbers based on investments on the commercial and R&D side.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX: